Who is sponsoring NCT02530697?

NCT02530697 is sponsored by University of Brasilia.

What condition does NCT02530697 study?

NCT02530697 studies Leishmaniasis.

What drugs are being tested in NCT02530697?

Interventions: Meglumine antimoniate, Miltefosine, Pentoxifylline.

What is the status of NCT02530697?

NCT02530697 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2024-01-11 · How we verify

The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: An Open-label, Randomized Clinical Trial in Brazil

NCT02530697 Phase 2 ACTIVE_NOT_RECRUITING

Mucocutaneous leishmaniasis is endemic in the central region of Brazil and other countries worldwide. The standard treatment with meglumine antimoniate has a high rate of important adverse effects. This interventional study consists in a randomized clinical trial to access efficacy and safety of the association of miltefosine and pentoxifylline compared to meglumine antimoniate and pentoxifyline.

Details

Lead sponsor	University of Brasilia
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	160
Start date	2015-08
Completion	2026-08

Conditions

Leishmaniasis

Interventions

Meglumine antimoniate
Miltefosine
Pentoxifylline

Primary outcomes

Cure — 90 days
Complete healing of previous lesions until the 90th day after the begin of the treatment
Failure — 90 days
Lesions fail to heal until the 90th day after the begin of the treatment
Relapse — 90 days
Lesions that reappear on the scar of a previously healed lesion

Countries

Brazil